Division of General Thoracic Surgery, Keio University School of Medicine, Tokyo, Japan.
J Thorac Cardiovasc Surg. 2012 Jul;144(1):87-93. doi: 10.1016/j.jtcvs.2012.03.034. Epub 2012 Apr 12.
To examine whether segmentectomy is radical for cT1N0M0 non-small cell lung cancer (NSCLC), a prospective single-arm study was performed at a single institution.
The criteria for segmentectomy were as follows: (1) peripheral-type cT1N0M0 NSCLC; (2) intraoperative frozen sections of sentinel nodes identified with isotope showing no metastasis; (3) surgical margins greater than 2 cm; (4) patient choice for segmentectomy; and (5) exclusion of right middle lobe tumors. From 2005 to 2009, of 245 patients with cT1N0M0 NSCLC, 195 (80%) were enrolled in the present study. Of these 195 patients, 179 ultimately underwent segmentectomy with systematic lymph node dissection. Of these 179 patients, 134 (75%) had tumors 2 cm or smaller, and 45 (25%) had tumors 2.1 cm to 3 cm. The median follow-up period was 43 months.
All 181 tumors from 179 patients were stage pN0. Of the 179 patients, 6 developed distant site recurrence and 3 local recurrence (ie, 1 developed pulmonary metastases within the same lobe 21 months after segmentectomy and 2 developed local recurrence at the surgical margin 60 and 62 months after segmentectomy, respectively). The 5-year overall survival was 94% for patients with tumors 2 cm or smaller and 81% for those with 2.1-cm to 3-cm tumors. Postoperative pulmonary function was preserved at 90% ± 12% of preoperative levels.
Segmentectomy with systematic lymph node dissection with a sufficient surgical margin could be a radical treatment for selected cT1N0M0/pN0 NSCLC while preserving pulmonary function. The surgical margin should be monitored for the development of local recurrence for a long period after segmentectomy.
为了研究段切除术是否适用于 cT1N0M0 期非小细胞肺癌(NSCLC),本研究在一家医院进行了前瞻性单臂研究。
段切除术的标准如下:(1)外周型 cT1N0M0 NSCLC;(2)术中使用同位素检测的前哨淋巴结冷冻切片无转移;(3)手术切缘大于 2cm;(4)患者选择段切除术;(5)排除右中叶肿瘤。2005 年至 2009 年间,245 例 cT1N0M0 NSCLC 患者中,195 例(80%)入组本研究。其中 195 例患者最终接受了系统性淋巴结清扫的段切除术。在这 179 例患者中,134 例(75%)肿瘤直径为 2cm 或更小,45 例(25%)肿瘤直径为 2.1cm 至 3cm。中位随访时间为 43 个月。
179 例患者的 181 个肿瘤均为 pN0 期。179 例患者中,6 例发生远处部位复发,3 例发生局部复发(即 1 例在段切除术后 21 个月发生同叶肺转移,2 例分别在段切除术后 60 个月和 62 个月发生手术切缘局部复发)。肿瘤直径为 2cm 或更小的患者 5 年总生存率为 94%,肿瘤直径为 2.1cm 至 3cm 的患者为 81%。术后肺功能保留在术前水平的 90%±12%。
对于选择性 cT1N0M0/pN0 NSCLC,系统性淋巴结清扫术加足够的手术切缘可以作为一种根治性治疗方法,同时保留肺功能。段切除术后应长期监测手术切缘,以防止局部复发。